VBL Therapeutics Announces Pricing of Initial Public Offering
TEL AVIV, Israel, Sept. 30, 2014 (GLOBE NEWSWIRE) -- VBL Therapeutics, a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced the pricing of its initial public offering of 6,666,667 of its ordinary shares at a public offering price of $6.00 per share, before underwriting discounts and commissions. In addition, VBL Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 ordinary shares at the same price, less underwriting discounts and commissions, to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on October 1, 2014 under the ticker symbol "VBLT." The offering is expected to close on October 6, 2014, subject to customary closing conditions.
Labaton Sucharow LLP
Labaton Sucharow LLP and Bernstein Litowitz Berger & Grossmann LLP Have Filed a Class Action Lawsuit on Behalf of Investors in Millennial Media, Inc. (MM)
NEW YORK, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Labaton Sucharow LLP ("Labaton Sucharow") and Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a securities class action lawsuit on behalf of the Public Employees' Retirement System of Mississippi in the U.S. District Court for the Southern District of New York. The lawsuit was filed on behalf of all persons or entities who, between March 28, 2012 and May 7, 2014, inclusive (the "Class Period"), purchased or otherwise acquired the common stock of Millennial Media, Inc. (NYSE:MM) ("Millennial Media" or the "Company"), as well as all persons or entities who purchased the common stock of Millennial Media pursuant and/or traceable to registered public offerings on or about March 28, 2012 (the Company's initial public offering, or "IPO") and October 24, 2012 (the "Secondary Offering").
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), has filed with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to receive approval for manufacturing, marketing, and product registration of the allogeneic or "off-the-shelf" Mesenchymal Stem Cell (MSC) product JR-031 for the treatment of acute graft versus host disease (GVHD) in children and adults.